TARSUS PHARMACEUTICALS, INC. Operating Expenses
TARSUS PHARMACEUTICALS, INC. (TARS) reported Operating Expenses of $160.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-02-27
- TARSUS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-06-30 was $20.50M, a 39.13% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-03-31 was $20.06M, a 11.70% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-12-31 was $14.79M, a 28.83% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-09-30 was $16.95M, a 67.09% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $160.60M, a 81.42% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $88.53M, a 27.96% increase from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. operating expenses for fiscal 2021 was $69.18M, a 156.26% increase from fiscal 2020.
- TARSUS PHARMACEUTICALS, INC. operating expenses for fiscal 2020 was $27.00M, a 528.15% increase from fiscal 2019.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-12-31 | $160.60M 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $88.53M 10-K · filed 2024-02-27 | |||
| 2022-06-30 | $20.50M 10-Q · filed 2022-08-11 | $40.56M 10-Q · filed 2022-08-11 | $55.35M derived: sum of 3 quarters · filed 2023-03-17 | $72.29M derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-03-31 | $20.06M 10-Q · filed 2022-05-11 | $34.85M derived: sum of 2 quarters · filed 2023-03-17 | $51.79M derived: sum of 3 quarters · filed 2023-03-17 | $66.53M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $31.73M derived: sum of 2 quarters · filed 2023-03-17 | $46.47M derived: sum of 3 quarters · filed 2023-03-17 | $69.18M 10-K · filed 2023-03-17 |
| 2021-09-30 | $16.95M 10-Q · filed 2021-11-10 | $31.68M derived: sum of 2 quarters · filed 2022-08-11 | $54.40M 10-Q · filed 2021-11-10 | $65.88M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $14.73M 10-Q · filed 2022-08-11 | $37.45M 10-Q · filed 2022-08-11 | $48.93M derived: sum of 3 quarters · filed 2022-08-11 | $59.07M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $22.72M 10-Q · filed 2022-05-11 | $34.20M derived: sum of 2 quarters · filed 2022-05-11 | $44.34M derived: sum of 3 quarters · filed 2022-05-11 | $47.60M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $11.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $21.62M derived: sum of 2 quarters · filed 2022-03-14 | $24.88M derived: sum of 3 quarters · filed 2022-03-14 | $27.00M 10-K · filed 2022-03-14 |
| 2020-09-30 | $10.14M 10-Q · filed 2021-11-10 | $13.40M derived: sum of 2 quarters · filed 2021-11-10 | $15.52M 10-Q · filed 2021-11-10 | $16.61M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $3.26M 10-Q · filed 2021-08-05 | $5.38M 10-Q · filed 2021-08-05 | $6.46M derived: sum of 3 quarters · filed 2021-08-05 | $7.10M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $2.12M 10-Q · filed 2021-05-11 | $3.20M derived: sum of 2 quarters · filed 2021-05-11 | $3.83M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.72M derived: sum of 2 quarters · filed 2021-03-31 | $4.30M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $633.00K 10-Q · filed 2020-11-25 | $3.21M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |